Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel Free REVB Stock Alerts

Revelation Biosciences (REVB) Competitors

Revelation Biosciences logo
$1.08 +0.04 (+3.94%)
As of 01:29 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

REVB vs. CTXR, QCLS, CYCN, LEXX, and BFRI

Should you buy Revelation Biosciences stock or one of its competitors? MarketBeat compares Revelation Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Revelation Biosciences include Citius Pharmaceuticals (CTXR), Mymd Pharmaceuticals (QCLS), Cyclerion Therapeutics (CYCN), Lexaria Bioscience (LEXX), and Biofrontera (BFRI). These companies are all part of the "pharmaceutical products" industry.

How does Revelation Biosciences compare to Citius Pharmaceuticals?

Citius Pharmaceuticals (NASDAQ:CTXR) and Revelation Biosciences (NASDAQ:REVB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment and valuation.

Citius Pharmaceuticals presently has a consensus target price of $5.00, indicating a potential upside of 850.57%. Given Citius Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Citius Pharmaceuticals is more favorable than Revelation Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Citius Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
Revelation Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Revelation Biosciences had 1 more articles in the media than Citius Pharmaceuticals. MarketBeat recorded 2 mentions for Revelation Biosciences and 1 mentions for Citius Pharmaceuticals. Citius Pharmaceuticals' average media sentiment score of 1.87 beat Revelation Biosciences' score of 0.63 indicating that Citius Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Citius Pharmaceuticals Very Positive
Revelation Biosciences Positive

Citius Pharmaceuticals is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Citius PharmaceuticalsN/AN/A-$37.43M-$2.13N/A
Revelation BiosciencesN/AN/A-$8.91M-$39.48N/A

Citius Pharmaceuticals has a beta of 0.98, indicating that its stock price is 2% less volatile than the broader market. Comparatively, Revelation Biosciences has a beta of -0.12, indicating that its stock price is 112% less volatile than the broader market.

Citius Pharmaceuticals' return on equity of -61.09% beat Revelation Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Citius PharmaceuticalsN/A -61.09% -35.36%
Revelation Biosciences N/A -107.65%-87.98%

16.9% of Citius Pharmaceuticals shares are held by institutional investors. Comparatively, 12.8% of Revelation Biosciences shares are held by institutional investors. 5.0% of Citius Pharmaceuticals shares are held by insiders. Comparatively, 4.8% of Revelation Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Citius Pharmaceuticals beats Revelation Biosciences on 10 of the 13 factors compared between the two stocks.

How does Revelation Biosciences compare to Mymd Pharmaceuticals?

Mymd Pharmaceuticals (NASDAQ:QCLS) and Revelation Biosciences (NASDAQ:REVB) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, valuation, institutional ownership, profitability, risk and analyst recommendations.

Mymd Pharmaceuticals is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mymd PharmaceuticalsN/AN/A-$11.63M-$20.69N/A
Revelation BiosciencesN/AN/A-$8.91M-$39.48N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mymd Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Revelation Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

9.6% of Mymd Pharmaceuticals shares are held by institutional investors. Comparatively, 12.8% of Revelation Biosciences shares are held by institutional investors. 0.9% of Mymd Pharmaceuticals shares are held by insiders. Comparatively, 4.8% of Revelation Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Mymd Pharmaceuticals' return on equity of -76.40% beat Revelation Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Mymd PharmaceuticalsN/A -76.40% -35.10%
Revelation Biosciences N/A -107.65%-87.98%

In the previous week, Revelation Biosciences had 1 more articles in the media than Mymd Pharmaceuticals. MarketBeat recorded 2 mentions for Revelation Biosciences and 1 mentions for Mymd Pharmaceuticals. Mymd Pharmaceuticals' average media sentiment score of 1.87 beat Revelation Biosciences' score of 0.63 indicating that Mymd Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Mymd Pharmaceuticals Very Positive
Revelation Biosciences Positive

Mymd Pharmaceuticals has a beta of 2.12, suggesting that its share price is 112% more volatile than the broader market. Comparatively, Revelation Biosciences has a beta of -0.12, suggesting that its share price is 112% less volatile than the broader market.

Summary

Mymd Pharmaceuticals and Revelation Biosciences tied by winning 5 of the 10 factors compared between the two stocks.

How does Revelation Biosciences compare to Cyclerion Therapeutics?

Cyclerion Therapeutics (NASDAQ:CYCN) and Revelation Biosciences (NASDAQ:REVB) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.

75.6% of Cyclerion Therapeutics shares are owned by institutional investors. Comparatively, 12.8% of Revelation Biosciences shares are owned by institutional investors. 34.3% of Cyclerion Therapeutics shares are owned by insiders. Comparatively, 4.8% of Revelation Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Cyclerion Therapeutics has a beta of 1.74, meaning that its share price is 74% more volatile than the broader market. Comparatively, Revelation Biosciences has a beta of -0.12, meaning that its share price is 112% less volatile than the broader market.

In the previous week, Revelation Biosciences had 1 more articles in the media than Cyclerion Therapeutics. MarketBeat recorded 2 mentions for Revelation Biosciences and 1 mentions for Cyclerion Therapeutics. Cyclerion Therapeutics' average media sentiment score of 1.87 beat Revelation Biosciences' score of 0.63 indicating that Cyclerion Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Cyclerion Therapeutics Very Positive
Revelation Biosciences Positive

Revelation Biosciences has a net margin of 0.00% compared to Cyclerion Therapeutics' net margin of -170.11%. Cyclerion Therapeutics' return on equity of -62.10% beat Revelation Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Cyclerion Therapeutics-170.11% -62.10% -55.14%
Revelation Biosciences N/A -107.65%-87.98%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cyclerion Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Revelation Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Cyclerion Therapeutics has higher revenue and earnings than Revelation Biosciences. Cyclerion Therapeutics is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cyclerion Therapeutics$2.07M7.73-$3.53M-$1.36N/A
Revelation BiosciencesN/AN/A-$8.91M-$39.48N/A

Summary

Cyclerion Therapeutics beats Revelation Biosciences on 9 of the 12 factors compared between the two stocks.

How does Revelation Biosciences compare to Lexaria Bioscience?

Revelation Biosciences (NASDAQ:REVB) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk.

12.8% of Revelation Biosciences shares are held by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are held by institutional investors. 4.8% of Revelation Biosciences shares are held by insiders. Comparatively, 8.4% of Lexaria Bioscience shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Lexaria Bioscience has a consensus price target of $1.50, suggesting a potential upside of 156.41%. Given Lexaria Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Lexaria Bioscience is more favorable than Revelation Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Revelation Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Lexaria Bioscience
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Revelation Biosciences and Revelation Biosciences both had 2 articles in the media. Revelation Biosciences' average media sentiment score of 0.63 beat Lexaria Bioscience's score of -0.57 indicating that Revelation Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
Revelation Biosciences Positive
Lexaria Bioscience Negative

Revelation Biosciences has a beta of -0.12, meaning that its stock price is 112% less volatile than the broader market. Comparatively, Lexaria Bioscience has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market.

Revelation Biosciences' return on equity of -107.65% beat Lexaria Bioscience's return on equity.

Company Net Margins Return on Equity Return on Assets
Revelation BiosciencesN/A -107.65% -87.98%
Lexaria Bioscience N/A -173.93%-138.79%

Revelation Biosciences has higher earnings, but lower revenue than Lexaria Bioscience. Lexaria Bioscience is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Revelation BiosciencesN/AN/A-$8.91M-$39.48N/A
Lexaria Bioscience$710K20.43-$11.90M-$0.47N/A

Summary

Lexaria Bioscience beats Revelation Biosciences on 8 of the 13 factors compared between the two stocks.

How does Revelation Biosciences compare to Biofrontera?

Revelation Biosciences (NASDAQ:REVB) and Biofrontera (NASDAQ:BFRI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and risk.

12.8% of Revelation Biosciences shares are owned by institutional investors. Comparatively, 10.1% of Biofrontera shares are owned by institutional investors. 4.8% of Revelation Biosciences shares are owned by insiders. Comparatively, 8.1% of Biofrontera shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Revelation Biosciences has higher earnings, but lower revenue than Biofrontera. Biofrontera is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Revelation BiosciencesN/AN/A-$8.91M-$39.48N/A
Biofrontera$41.71M0.33-$10.54M-$0.97N/A

Revelation Biosciences has a net margin of 0.00% compared to Biofrontera's net margin of -25.66%. Revelation Biosciences' return on equity of -107.65% beat Biofrontera's return on equity.

Company Net Margins Return on Equity Return on Assets
Revelation BiosciencesN/A -107.65% -87.98%
Biofrontera -25.66%-515.34%-53.91%

Revelation Biosciences has a beta of -0.12, meaning that its stock price is 112% less volatile than the broader market. Comparatively, Biofrontera has a beta of 0.81, meaning that its stock price is 19% less volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Revelation Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Biofrontera
2 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.67

In the previous week, Biofrontera had 2 more articles in the media than Revelation Biosciences. MarketBeat recorded 4 mentions for Biofrontera and 2 mentions for Revelation Biosciences. Biofrontera's average media sentiment score of 0.71 beat Revelation Biosciences' score of 0.63 indicating that Biofrontera is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Revelation Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Biofrontera
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Biofrontera beats Revelation Biosciences on 9 of the 14 factors compared between the two stocks.

Get Revelation Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for REVB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding REVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

REVB vs. The Competition

Export
MetricRevelation BiosciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$4.21M$3.66B$6.79B$12.62B
Dividend YieldN/A2.19%2.68%8.43%
P/E Ratio-0.0321.2727.0424.39
Price / SalesN/A314.78521.7491.34
Price / CashN/A143.6648.5959.39
Price / Book0.858.5110.836.31
Net Income-$8.91M$23.83M$3.59B$331.45M
7 Day Performance10.61%-2.88%-1.30%0.26%
1 Month Performance9.37%5.76%2.97%-0.64%
1 Year Performance-90.56%51.80%28.58%20.24%

Revelation Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
REVB
Revelation Biosciences
1.2891 of 5 stars		$1.08
+3.9%		N/A-90.5%$4.23MN/AN/A10
CTXR
Citius Pharmaceuticals
2.7747 of 5 stars		$0.56
-4.5%		$5.00
+797.2%		-68.1%$15.30MN/AN/A20
QCLS
Mymd Pharmaceuticals
0.6068 of 5 stars		$3.66
-0.3%		N/AN/A$15.26MN/AN/A6
CYCN
Cyclerion Therapeutics
0.9737 of 5 stars		$3.47
-0.3%		N/A+16.1%$15.03M$2.07MN/A30
LEXX
Lexaria Bioscience
1.7931 of 5 stars		$0.61
+14.1%		$1.50
+147.9%		-29.6%$15.00M$710KN/A7

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:REVB) was last updated on 7/15/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
DOJ Admits It In Court—Your Cash Can Be Seized Without Warning
The Department of Justice recently argued in court that cash may not be legally your property - raising concer...
Priority Gold | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel